Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
← catalyst calendarSponsored by Veru Inc. (industry) · VERU — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
168actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | 2025-04-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-22 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Muscle Loss
- Obesity
Interventions
- Drug: Enobosarm
- Drug: Semaglutide — also filed as Wegovy
Primary outcome
what the primary-completion date above is the date OFThe primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.
measured Day 112
Permalink · VERU's whole pipeline · Catalyst calendar · Every registered study · What changed